

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for July 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Laboratoire Riva Inc.	Riva-Levofloxacin	Levaquin	LEVOFLOXACIN HEMIHYDRATE	750 mg	tablet	02492741
Marcan Pharmaceuticals Inc.	Mar-Tranexamic Acid	Cyklokapron	TRANEXAMIC ACID	500mg	tablet	02496232
Nora Pharma	NRA-Zopiclone	Imovane	ZOPICLONE	5mg	tablet	02477378
Nora Pharma	NRA-Zopiclone	Imovane	ZOPICLONE	7.5mg	tablet	02477386

Natco Pharma (Canada) Inc.	Nat-Lanthanum	Fosrenol	LANTHANUM CARBONATE DIHYDRATE	250 mg	tablet (chewable)	02498731
Natco Pharma (Canada) Inc.	Nat-Oseltamivir	Tamiflu	OSELTAMIVIR PHOSPHATE	6 mg/mL	oral, powder for suspension - 65mL bottle	02499894